Erratum: History and progress of hypotheses and clinical trials for Alzheimer’s disease (Signal Transduction and Targeted Therapy, (2019), 10.1038/s41392-019-0063-8)

Abstract

Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-019-0063-8, published online 23 August 2019 Since the publication of this Review Article, we noticed several mistakes in Table 2 and the Perspective section that need to be corrected immediately. In Table 2, the status of AAB-003 Phase I trial is completed. In addition, the status of GV-971 Phase III trial is completed in China. The correct portion of Table 2 is displayed as below. In the perspective section, the sigma-1 receptor activator Anavex 2-73 has entered a phase III clinical trial but it was not granted fast-track status by the FDA. Therefore, the texts should be corrected to “In addition, fluoxetine can bind to the endoplasmic reticulum protein sigma-1 receptor.418 Sigma-1 receptor ligands can enhance acetylcholine secretion.419,420 The sigma-1 receptor is located in the mitochondrion-associated ER membrane so that the activation of the sigma-1 receptor can prolong Ca2+ signaling in mitochondria.421 Consequently, the local and specific elevation of [Ca2+] in the mitochondrial matrix can enhance ATP synthesis,422,423 which ameliorates hypometabolism. Interestingly, Anavex 2-73, a sigma-1 receptor activator is now in phase III clinical trial.” The key messages of the article are not affected by these corrections. We apologize for these inadvertent mistakes. (Table Presented).